Endomagnetics gets FDA's IDE approval to begin clinical trial of SentiMag and Sienna+
 

Cancer healthcare company Endomagnetics announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration to initiate a pivotal clinical trial to evaluate the safety and effectiveness of the SentiMag and Sienna+ magnetic sentinel lymph node biopsy system in the management of breast cancer.

More...